Tevogen Bio

Yahoo Finance • 2 days ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Bio Inc Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly every time, dramatically rai... Full story

Yahoo Finance • 16 days ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Bio IncMittul Mehta Headshot PR WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head o... Full story

Yahoo Finance • 30 days ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Bio Inc WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting ru... Full story

Yahoo Finance • 2 months ago

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Inc Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating c... Full story

Yahoo Finance • 2 months ago

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Tevogen Bio Inc WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has pub... Full story

Yahoo Finance • 2 months ago

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Tevogen Bio Inc17,428-square-foot facility in New Jersey WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428... Full story

Yahoo Finance • 2 months ago

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

Tevogen Bio Inc Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies Initiative to support Tevogen Bio’s ExacTcell™ pipeline with a goal of enhancing commercial viability and shareholde... Full story

Yahoo Finance • 2 months ago

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen Bio Inc Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and ac... Full story

Yahoo Finance • 4 months ago

Tevogen expands headquarters in Warren, New Jersey

Tevogen (TVGN) announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. The expanded space will centralize cross-functional teams, including executive leader... Full story

Yahoo Finance • 4 months ago

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio Inc WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.... Full story

Yahoo Finance • 4 months ago

Tevogen Peports Plans to Increase the Target Population for TVGN 489

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above.Tevogen reports plans to increase the target population for TVGN 489 A lab... Full story